Advisors Management Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Advisors Management Group’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,270	Closed	-$2K	–	167
2025 Q4	$2K	Hold	10,270	–	–	﹤0.01%	158
2025 Q3	$2K	Hold	10,270	–	–	﹤0.01%	153
2025 Q2	$2K	Hold	10,270	–	–	﹤0.01%	148
2025 Q1	$2K	Hold	10,270	–	–	﹤0.01%	147
2024 Q4	$3K	Hold	10,270	–	–	﹤0.01%	150
2024 Q3	$3K	Hold	10,270	–	–	﹤0.01%	150
2024 Q2	$4K	Hold	10,270	–	–	﹤0.01%	154
2024 Q1	$5K	Hold	10,270	–	–	﹤0.01%	158
2023 Q4	$7K	Hold	10,270	–	–	﹤0.01%	154
2023 Q3	$9K	Hold	10,270	–	–	﹤0.01%	140
2023 Q2	$6K	Hold	10,270	–	–	﹤0.01%	141
2023 Q1	$6K	Hold	10,270	–	–	﹤0.01%	140
2022 Q4	$8K	Buy	+10,270	New	+$8K	﹤0.01%	133

Other funds holding NWBO

KFA

Kelleher Financial Advisors New York $395M AUM 12.89% 1-Year Est. Return

VWA

VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

McIlrath & Eck Arlington, Washington $1.35B AUM 15.78% 1-Year Est. Return

Advisors Management Group's NWBO Position: Q1 2026 in Review

Advisors Management Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2026, closing a stake of 10,270 shares — an estimated $2K sold.

Advisors Management Group first reported a position in NWBO in Q4 2022 and held it in 13 quarters. The position peaked at $9K in Q3 2023. 8 funds tracked by Wall St. Rank hold NWBO as of Q1 2026.

Advisors Management Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2026 after selling out during the quarter.
Advisors Management Group sold 10,270 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2026, an estimated $2K.
Advisors Management Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2022 and held it in 13 quarters.
Advisors Management Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $9K in Q3 2023.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2026.

Based on Advisors Management Group's 13F filing for Q1 2026, filed 1 May 2026.